Decreasing the Use of Unmodified Electroconvulsive Therapy (ECT) in an Indian Hospital

Not Applicable

Completed

• Conditions: Major Depressive Disorder; Bipolar Disorder; Schizophrenia
• Interventions: Drug: Propofol

• Registration Number: NCT01526395
• Lead Sponsor: Johns Hopkins University

Brief Summary

In developing countries, electroconvulsive therapy (ECT) is typically delivered without the use of an anesthetic prior to the treatment, known as unmodified ECT. This interventional study aims to decrease the practice of unmodified ECT at Chhatrapati Shahuji Maharaj Medical University, U.P. \& G.M. \& Associated Hospitals (C.S.M) by administering a low dose anesthetic (propofol) prior to ECT delivery. In so doing, the investigators hope to facilitate the transition from unmodified to modified ECT without incurring excessive costs to the center. It is hypothesized that ECT patients will opt for modified treatment, that adverse effects will be minimal, and that costs will not rise prohibitively.

Detailed Description

Patients that are currently receiving unmodified ECT at C.S.M Hospital will be eligible for the first phase of the study in which only data is collected. Three months after study start, patients who are to receive ECT for a psychiatric disorder will be eligible to participate in the intervention (introduction of propofol at a low dose prior to ECT). Data collection will include information such as demographics, ratings scales, seizure length, anxiety level, adverse events, and number of treatments.

Study Timeline

• Study Start: 2011-08
• Study First Submitted: 2011-12-21
• Study First Submitted QC: 2012-02-01
• Study First Posted: 2012-02-03
• Primary Completion: 2012-04
• Study Completion: 2012-04
• Status Verified: 2013-04
• Last Update Submitted: 2013-04-01
• Last Update Posted: 2013-04-04

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 99

Inclusion Criteria

• Subjects are any psychiatric patients at C.S.M. for whom ECT is recommended by their doctor, whether or not they actually receive ECT.
• Subjects must also have an American Society for Anesthesiologists (ASA) rating score of 1 (completely healthy) or 2 (mild systemic disease) with stable symptoms and laboratory values.
• Subjects must be between the ages of 18 to 65 years old and be able to give informed consent.

Exclusion Criteria

• Patients who speak neither English nor Hindi.
• History of or anatomical evidence for a difficult airway being a short mandible, micrognathia, large tongue or large goiter, arthritis of the jaw or neck, or enlarged tonsils. For this reason we will also exclude patients with a BMI > 28.
• Respiratory tract disease including asthma, respiratory infection, chest wall disease, chronic obstructive pulmonary disease, obstructive sleep apnea, or other disorder which might compromise the airway. Patients who smoke 15 or more cigarettes per day will be excluded unless abstinent for at least 10 days, to reduce the risk of respiratory complications.
• Patients who receive modified ECT during the first phase of the study.
• Pregnant women or women who are breastfeeding.
• Hypersensitivity to propofol or any of its components.
• Patients who are hemodynamically unstable or who have impaired cardiac function.
• BMI < 18.
• Patients with a history of epilepsy

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Low Dose Propofol	Propofol	Subjects will be given low dose propofol prior to ECT.

Primary Outcome Measures

Name	Time	Method
Percentage of patients receiving ECT who agree to the modified form of treatment after it is offered.	6 months

Secondary Outcome Measures

Name	Time	Method
Rate at which ECT is offered and refused.	6 months
Change in patient anxiety measured by the state portion of the State-Trait Anxiety Inventory.	Baseline and completion of ECT treatments or up to 6 months, whichever comes first
Inpatient length of stay calculated from onset of ECT administration.	6 months
Number of ECTs required to complete a course of treatment	6 months
Changes in scales used to assess severity of symptoms. The investigators will record changes in the Hamilton Depression Rating Scale, the Young Mania Rating Scale, the Brief Psychiatric Rating Scale and the Clinical Global Impression Severity scale.	Baseline and completion of ECT treatments or up to 6 months, whichever comes first
Cognitive changes, monitored by the Mini Mental State Examination (MMSE)	Baseline and completion of ECT treatments or up to 6 months, whichever comes first
Monitoring of adverse effects such the occurence of emergent delirium, headaches, muscle aches, nausea and vomiting, and fractures and dislocations.	Baseline and completion of ECT treatments or up to 6 months, whichever comes first
Monitoring of delirium using the test with the Confusion Assessment Method for the ICU (CAM-ICU).	Baseline and completion of ECT treatments or up to 6 months, whichever comes first

Trial Locations

Locations (1)

Chhatrapati Shahuji Maharaj Medical University, U.P. & G.M. & Associated Hospitals; 🇮🇳 Lucknow, Uttar Pradesh, India